Fly News Breaks for February 19, 2020
Feb 19, 2020 | 05:09 EDT
The Zynteglo European launch has been underway for one month in Germany and Bluebird Bio expects to treat the first patient in the first half, Piper Sandler analyst Tyler Van Buren tells investors in a research note. However, the U.S. Biologics License Application has been pushed into the second half given the FDA's request for more information pertaining to release assays, adds the analyst. Van Buren likes the company's prospects, but remains Neutral rated on the shares saying he has more conservative expectations than the Street for the more immediate Zynteglo launch.
News For BLUE From the Last 2 Days
There are no results for your query BLUE